Work with your provider to titrate your dose, starting with a low dose and gradually increasing it from one week to the next
There have been several previous studies addressing changes in diuretic and natriuretic responses to GLP-1 in disease conditions [55,56,57]
However, there are critical distinctions: Rodents have a much higher density of GLP-1 receptors on thyroid C-cells than humans Human thyroid C-cells show minimal GLP-1 receptor expression No causal link between semaglutide and thyroid cancer has been established in human clinical trials involving over 10,000 participants (Bjerre Knudsen et al., 2010, Endocrinology ) A large pharmacovigilance study published in Diabetes Care found no increased risk of thyroid cancer among GLP-1 receptor agonist users compared to other diabetes medications (Bezin et al., 2023, Diabetes Care ) Despite this reassurance, the following patients should avoid semaglutide: Those with a personal history of medullary thyroid carcinoma (MTC) Those with a family history of MTC Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) For patients with common hypothyroidism (typically Hashimotos thyroiditis or post-surgical hypothyroidism), these contraindications do not apply
Weight Loss: Due to its appetite-suppressing effects, patients often see significant weight loss, which can also help improve other health markers such as blood pressure and cholesterol levels
I have energy, and I am no longer using a cane everywhere
Changing injection sites will not stop nausea or reduce appetite changes
